Abstract
Background This study aims to explore how radiological findings contribute to distinguishing between benign and malignant diseases in patients with solitary cavitary lesions detected on CT.
Methods We retrospectively assessed lesion size, cavity wall thickness, and additional parenchymal findings in diagnosing benign or malignant disease in these patients. Our study investigated the incidence and etiology of solitary pulmonary cavities. CT scans were reviewed by a single radiologist with expertise in thoracic radiology. The study was conducted using two 64-multidetector CT systems, and measurements of lesion size and cavity wall thickness were recorded on axial images. Consolidation and centrilobular nodules were assessed based on predefined criteria. Receiver operating characteristic curves were generated to determine optimal cut-off points for distinguishing between malignant and non-malignant lesions based on cavity wall thickness.
Results Non-malignant lesions accounted for 47.9% of cases, with active pulmonary tuberculosis being the most common diagnosis. In the malignant group, primary lung cancer predominated, squamous cell carcinoma being the most prevalent subtypes. Significant differences were noted between malignant and non-malignant cases regarding average maximum wall thickness and lesion diameter. Presence of perilesional consolidation or centrilobular nodules favored non-malignant diagnoses. Maximum wall thickness thresholds of 7.2 mm or 23 mm were most accurate in suggesting non-malignant and malignant etiologies, respectively.
Conclusions In conclusion, CT findings revealed significant distinctions between malignant and non-malignant solitary lung cavities; benign lesions generally exhibited smaller and thinner cavity walls, with accompanying perilesional parenchymal findings observed in benign lesions of infectious origin but not in malignant lesions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Bolu Abant Izzet Baysal University ethics committee (2021-233)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Zeliha Cosgun, Bolu Abant Izzet Baysal University, Izzet Baysal Training and Research Hospital, Bolu/Turkey.
Conflict of Interest: None to declare.
Financial disclosure: This work has not been funded by any organization.
Data Availability
Data cannot be shared publicly because of Due to the law on the protection of personal rights. Data are owned by a third-party organization, (Research Ethics Committee of AIBU, contact email is boluetikibu.edu.tr).
